Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune Inc (NQ: ALT )

6.740 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune Inc

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
ROSEN, A RANKED AND LEADING FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
WHY: NEW YORK, NY - (NewMediaWire) - May 12, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune,... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
ROSEN, A LEADING NATIONAL FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A LEADING NATIONAL FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
WHY: NEW YORK, NY - (NewMediaWire) - May 11, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune,... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Altimmune, Inc. Investor Notice: Robbins LLP Reminds Stockholders of the Altimmune, Inc. (ALT) Class Action
From Robbins LLP
Via Business Wire
ALT Stock Earnings: Altimmune Beats EPS for Q1 2024
ALT stock results show that Altimmune beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT
WHY: NEW YORK, NY - (NewMediaWire) - May 10, 2024 - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Altimmune,... 
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Peering Into Altimmune's Recent Short Interest
Via Benzinga
How Is The Market Feeling About Altimmune?
Via Benzinga
ALT INVESTOR NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc. (ALT) Investors
From Law Offices of Howard G. Smith
Via Business Wire
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Stockholder Alert: Robbins LLP Informs Investors of the Class Action Filed Altimmune, Inc. (ALT)
From Robbins LLP
Via GlobeNewswire
Altimmune, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit
From Block & Leviton LLP
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALT
From Rosen Law Firm
Via Business Wire
ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
Jim Cramer Calls Nutanix 'The Perfect Enterprise Software Company For The Moment'
Cramer discusses Agnico Eagle Mines, Nutanix, Altimmune, CVR Energy and Quanta Services on CNBC's "Mad Money." 
Via Benzinga
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Deutsche Bank, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly. 
Via InvestorPlace
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio 
Via MarketBeat
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
Altimmune has a modest market cap but an incredibly promising GLP-1 drug. 
Via The Motley Fool
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one. 
Via InvestorPlace
Forget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate. 
Via The Motley Fool
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market 
Via MarketBeat
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.